Keros Therapeutics: Diverging Signals Create Investor Crossroads
Published on 11/29/2025 at 06:53 | Redaktion boerse-global.de
Keros Therapeutics (KROS) finds itself at the center of conflicting market narratives this Friday, presenting investors with a complex puzzle. The biotechnology firm is simultaneously the subject of conservative price targeting from Bank of America and top-tier value stock recognition from quantitative analysts.
The institutional landscape for Keros Therapeutics showed notable division during the third quarter of 2025. While 90 investment firms reduced their holdings, 85 institutions chose to increase their exposure to the biotech company.
Key institutional movements included:
* Goldman Sachs expanded its position by 441,923 shares, representing a 50.0% increase
* Logos Global Management substantially reduced its stake by 1.15 million shares, a 57.5% decrease
* Morgan Stanley Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
